GSK Plc said it won US approval for a drug to treat severe asthma, boosting its prospects as a potential blockbuster.

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Exdensur ...

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...

The U.S. health regulator has approved GSK's add-on drug to treat severe asthma, the drugmaker said on Tuesday, paving the ...

Latozinemab failure, with Nivisnebart Phase 2 data as the next key catalyst. Click here to read more about ALEC stock.

The MHRA has approved depemokimab as an add on treatment for severe asthma and chronic rhinosinusitis with nasal polyps.

"Gijs brings an exceptional blend of scientific depth, clinical insight, and strategic leadership to our board of directors," said Calluna CEO Mark Gaffney. "We are thrilled to welcome him and are ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has agreed ...

(Alliance News) - GSK PLC on Monday said Exdensur has been approved in the UK, for the treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps.

UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged ...

The combination was well tolerated: no treatment-related deaths occurred, and only 6% (2 patients) were discontinued due to toxicity. The most common treatment-related adverse events were anemia (69%) ...

Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years.Results suggest that nuclear GSK-3β ...